A Reading Desk, Not a Clinic or a Store

What this site is

Peptide Messengers is an independent research digest covering five research peptides — semaglutide, ipamorelin, GHK-Cu, PT-141, and MOTS-c — through a single organizing idea: each one is a chemical messenger, a signal the body either already uses or closely borrows the receptor logic of. That frame is a reading lens, not a claim that the five compounds share a risk profile, an approval status, or a level of evidence. They do not, and the site is built to keep those differences visible rather than smoothing them over for a tidier narrative.

We are not a clinic, a pharmacy, or a vendor. Nothing on this site is for sale, and no page recommends a dose for any individual. Where a compound has an FDA-approved indication, we say so and cite the trials behind it. Where it does not, we say that plainly too.

How we read the literature

Every quantitative claim on this site — a percentage, a hazard ratio, a sample size, a half-life — traces to a specific cited source, numbered and listed on the references page. We distinguish three tiers of evidence throughout: controlled human trials, animal and cell studies, and anecdotal community reports, and we label anecdotal material explicitly wherever it appears rather than blending it with clinical findings. When a finding is negative, mixed, or contested — a missed trial endpoint, a disputed re-analysis, an unconfirmed cancer signal — we report that as carefully as we report a positive result. A literature digest that only reports favorable findings is not doing the job a reader actually needs from it.

What we will not do

We will not recommend a human dose for any compound, describe a purchase pathway, or use second-person language telling a reader what to take. We will not present a research-community anecdote as clinical evidence, and we will not omit a safety caution because it is inconvenient to the compound's popularity. Two of these five compounds — semaglutide and PT-141 — have FDA-approved forms for specific indications; the other three do not, and treating research-chemical material as equivalent to an approved pharmaceutical would be a real disservice to a reader trying to understand actual risk.

Who maintains this

Peptide Messengers is edited and maintained as an independent literature digest. Content is sourced from peer-reviewed journals, clinical-trial registries, regulatory labeling, and, where explicitly labeled, patient- and research-community reporting. See Contact for how to reach the editorial desk.